Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

View Full Paper
Ask AI
Bookmark
Share

Authors

VGVikas A. GuptaANAjay K. Nooka

Discussion

Loading...

Member takes

Overview

Retrospective analysis identifies predictors of long progression-free survival in NDMM patients treated with RVD induction and maintenance therapy.

Key Points

  • To identify and characterize NDMM patients achieving prolonged progression-free survival following RVD induction and risk-adapted maintenance therapy.
  • Conducted a retrospective cohort analysis of 1000 NDMM patients treated with RVD and maintenance from 2007-2016.
  • Identified 143 patients with a progression-free survival of at least 10 years among eligible patients.
  • Collected demographics, clinical characteristics, and outcomes from an institutional myeloma database.
  • 143 NDMM patients achieved a progression-free survival of ≥10 years.
  • Long-term responders more likely to be ≤65 years old and stage R-ISS I.
  • 85.9% of long-term responders received maintenance therapy compared to 75.3% in the overall cohort.

Cite This Study

Gupta et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7fchttps://doi.org/10.1182/blood-2025-2812
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression2025
  2. 2P54 | EVOLVING OUTCOMES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE: 30-YEARS SINGLE CENTER EXPERIENCE2026
  3. 3Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.2025
  4. 4P24 | APPROACHING CURE IN MULTIPLE MYELOMA: A DUAL-CENTER EXPERIENCE AMONG PATIENTS DIAGNOSED BEFORE 20102026 · 1 citations
  5. 5Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study2025